Xeris Pharmaceuticals

Xeris Pharmaceuticals' mission is to develop and commercialize novel, ready-to-use injectable drug formulations that overcome stability and delivery challenges. The company has successfully leveraged its proprietary technology platforms to bring multiple products to market, including Gvoke® for severe hypoglycemia and Keveyis® for primary periodic paralysis. Its strategy focuses on expanding its commercial portfolio, advancing a deep pipeline of 19+ candidates, and forming strategic partnerships to apply its formulation expertise to a broad range of therapeutics. Xeris operates as an integrated biopharma company, controlling development, manufacturing, and commercialization.

Xeris's proprietary XeriSol™ and XeriJect™ platforms enable the development of ready-to-use, room-temperature stable liquid and suspension formulations of peptides, proteins, and small molecules, eliminating the need for reconstitution or refrigeration.

Xeris faces product-level competition from other glucagon therapies and rare disease treatments. At the platform level, it competes with other drug delivery technology firms, but differentiates itself through its proven, specialized expertise in ready-to-use, stable liquid formulations of complex molecules.